Web Exclusives

The ASCEND trial confirmed that acalabrutinib, a next-generation targeted treatment, is more effective than traditional chemoimmunotherapy in patients with relapsed chronic lymphocytic leukemia.

Recently reported data show that fixed-duration treatment with venetoclax and obinutuzumab for 12 months is effective and tolerable in some patients with chronic lymphocytic leukemia.

Patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who require systemic therapy have a new chemotherapy-free combination regimen to consider.

The chemotherapy-free combination of venetoclax plus obinutuzumab has shown efficacy and tolerability in older patients with chronic lymphocytic leukemia. Adding acalabrutinib, a new targeted agent, may enhance the clinical benefits of this regimen, according to results of a clinical trial.

Cancer specialists are now able to use a new scoring system to decide when to start treatment for patients who have been diagnosed with chronic lymphocytic leukemia.

Alliance A041702 is a large clinical trial that is exploring whether adding venetoclax to the combination of ibrutinib and obinutuzumab can improve outcomes in patients with chronic lymphocytic leukemia.

According to results from a recent study, patients with chronic lymphocytic leukemia are more likely to survive for longer time periods if their posttreatment tests show no evidence of residual disease.

Pharmacists who specialize in managing medications for people with cancer offer unique services and support, especially for patients who are treated with targeted agents.

Government rules regarding the protection and sharing of health information and medical records can be confusing. It is important for people with cancer and their caregivers to understand how to protect their health information.